{"url_path":"/sec/apm/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","accession_number":"0001213900-26-079416","cik":"0001734005","ticker":"APM","issuer_name":"Niki BioSolutions, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","primary_entity_key":"0001734005","primary_entity_name":"Niki BioSolutions, Inc."},"word_count":426,"has_tables":true,"body_markdown":"false\n--12-31\n0001734005\n\n0001734005\n\n2026-07-20\n2026-07-20\n\n0001734005\n\ndei:FormerAddressMember\n\n2026-07-20\n2026-07-20\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549**\n\n** **\n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n** **\n\n**Pursuant to Section 13 OR 15(d) of The Securities\nExchange Act of 1934**\n\n \n\n  Date of Report (Date of earliest event reported): **July 20, 2026**\n\n \n\n**Niki BioSolutions, Inc.**\n\n(Exact name of Registrant as Specified in Its Charter)\n\n \n\n**Delaware**\n \n**001-38764 **\n \n**42-3265309**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n \n**116\nVillage Boulevard****, Suite 200****,\nPrinceton****, NJ****08540**\n \n\n \n(Address of Principal Executive Offices, including zip code)\n \n\n \n\nRegistrant’s Telephone\nNumber, Including Area Code: 609-951-2222\n\n \n\nAptorum Group Limited\n\n17 Hanover Square\n\nLondon W1S 1BN, United Kingdom\n\n(Former Name or Former Address, if Changed Since Last Report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement communications pursuant to Rule 14d-2(b)\nunder the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement communications pursuant to Rule 13e-4(c)\nunder the Exchange Act (17 CFR 240.13e-4(c))\n\n** **\n\n**Securities registered pursuant to Section 12(b)\nof the Act:**\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on\nwhich registered**\n\nCommon stock, par value $0.0001 per share\n \nNIKI\n \nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Introductory Note**\n\n \n\nTerms used in this Current Report on Form 8-K\n(this “Report”) but not defined herein, or for which definitions are not otherwise incorporated by reference herein, shall\nhave the meaning given to such terms in the definitive proxy statement/prospectus (as supplemented or amended, the “Proxy Statement/Prospectus”),\noriginally filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission (the “SEC”) on October 6, 2025, by\nAptorum Group Limited, a Cayman Islands exempted company with limited liability (“Aptorum”), and which forms a part of the\nRegistration Statement on Form S-4 (Registration No. 333-290742), which the SEC declared effective on May 13, 2026."}